NCT02376699 2023-05-01Safety Study of SEA-CD40 in Cancer PatientsSeagen Inc.Phase 1 Terminated159 enrolled
NCT03841110 2023-05-01FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsFate TherapeuticsPhase 1 Completed37 enrolled